Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the olympus AU400 analyzer

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 688-694

  Beumer, Jan H ^a   Boisdron Celle, M ^b   Clarke, William ^c   Courtney, Jodi B ^d   Egorin, Merrill J ^a   Gamelin, Erick ^b   Harney, Rebecca L ^d   Hammett Stabler, Catherine ^e   Lepp, Sandy ^f   Li, Yunying ^d   Lundell, Gregory D ^d   McMillin, Gwen ^g   Milano, Gerard ^h   Salamone, Salvatore J ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b Paul Papin Cancer Center   (France)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d SALADAX BIOMEDICAL INC   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^f Olympus Instruments   (United States)

^g ARUP LABORATORIES   (United States)

^h CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

5 fluorouracil; Chemotherapy; Drug management; Immunoassay

Indexed keywords

CAPECITABINE; DIHYDROFLUOROURACIL; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; NANOPARTICLE; OXALIPLATIN; TEGAFUR;

ACCURACY; ANALYZER; ARTICLE; CALIBRATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CROSS REACTION; DRUG BLOOD LEVEL; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MULTICENTER STUDY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 72949093283     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/ftd.0b013e3181b9b8c0     Document Type: Article

References (39)

1. Scrip's Cancer Chemotherapy Report, Scrip World Pharmaceutical News. London, United Kingdom: PJB Publications Ltd; 2002.
2. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer Status of the art. Crit Rev Oncol Hematol. 1999;30:71-79.
3. de Jonge ME, Huitema AD, Schellens JH, et al. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet. 2005;44:147-173.
4. Hon YY, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem. 1998;44:388-400.
5. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005;5:447-458.
6. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults 1991-2001. J Nat Cancer Inst. 2002;94:1883-1888.
7. Gamelin E, Boisdron-Celle M, Guérin-Meyer V, et al. Correlation between uracil and dihydrouracil plasma ratio, and 5-fluorouracil pharmacokinetic parameters and tolerance in patients with advanced colorectal cancer. A potential interest for predicting 5-FU toxicity and for determining optimal 5-FU dosage. J Clin Oncol. 1999;17:1105-1110.
8. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175.
9. Kirkwood JM, Ensminger W, Rosowsky A, et al. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil concurrent thymi-dine infusions in a Phase I trial. Cancer Res. 1980;40:107-113.
10. Hillcoat BL, McCulloch PB, Figueredo AT, et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer. 1978;38:719-724.
11. Trump DL, Egorin MJ, Forrest A, et al. Pharmacokinetic and pharma-codynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991;9:2027-2035.
12. van Groeningen CJ, Pinedo HM, Heddes J, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 1988;48:6956-6961.
13. Yoshida T, Araki E, Iigo M, et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother Pharmacol. 1990;26:352-354.
14. Au JL, Rustum YM, Ledesma EJ, et al. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res. 1982;42:2930-2937.
15. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287-290.
16. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994;12:1291-1295.
17. Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039-2045.
18. Ychou M, Duffour J, Pinguet F, et al. Individual 5FU-dose adaptation schedule using bimonthly pharmacokinetically modulated LV5FU2 regimen: a feasibility study in patients with advanced colorectal cancer. Anticancer Res. 1999;19:2229-2235.
19. Ychou M, Duffour J, Kramar A, et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother Pharmacol. 2003;52:282-290.
20. Gamelin E, Boisdron-Celle M, Guerin-Meyer V, et al. 5-FU dose monitoring and prevention of oxaliplatin-induced neurotoxicity in FOLFOX 4 regimen. Results of a phase II study. In Gutenburg SM ed. 2008 Gastrointestinal Cancers Symposium, Proceedings Book. Alexandria: American Society of Clinical Oncology, 2008:283. Abstract 431.
21. Capitain O, Asevoaia A, Boisdron-Celle M, et al. Influence of pharmacogenetic and epigenetic factors on 5-fluorouracil and irinotecan (FOLFIRI) efficacy and tolerance in patients treated for advanced colorectal cancer. In Gutenburg SM ed. 2008 Gastrointestinal Cancers Symposium, Proceedings Book. Alexandria: American Society of Clinical Oncology, 2008:282. Abstract 429.
22. Gamelin E, Delva R, Jacob J, et al. Individual 5-fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099-2105.
23. Smith CG, Grady JE, Kupiecki FP. Blood and urine levels of antitumor agents determined with cell culture methods. Cancer Res. 1965;25: 241-245.
24. Cohen JL, Brennan PB. GLC assay for 5-fluorouracil in biological fluids. J Pharm Sci. 1973;4:572-575.
25. Hillcoat BL, Kawai M, McCulloch PB, et al. A sensitive assay of 5-fluorouracil in plasma by gas chromatography-mass spectrometry. Br J Clin Pharmacol. 1976;38:719-724.
26. Christophidis N, Mihaly G, Vajda F, et al. Comparison of liquid-and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem. 1979;25:83-87.
27. Beumer JH, Courtney J, Stocker D, et al. Highlights from: 5-fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Assay for 5-fluorouracil in Biological Fluidsm Measurement by liquid chromatography/tandem mass spectrometry and stability in human blood and plasma. Clin Colorectal Cancer. 2007;6:417-419.
28. Kosovec JE, Egorin MJ, Gjurich S, et al. Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:224-230.
29. Salamone SJ, Li Y, Courtney J, et al. Highlights from: 5-fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; 5-fluorouracil determination in plasma by rapid nanoparticle immunoassay. Clin Colorectal Cancer. 2007;6:419-420.
30. Li Z, Goc-Szkutnicka K, McNally AJ, et al. Synthesis of new d-propoxyphene derivatives and the development of a microparticle-based immunoassay for the detection of propoxyphene and norpropox-yphene. Bioconjug Chem. 1997;8:896-905.
31. Wu R, McNally AJ, Pilcher IA, et al. New synthesis and characterization of (+)-lysergic acid diethylamide (LSD) derivatives and the development of a microparticle-based immunoassay for the detection of LSD and its metabolites. Bioconjug Chem. 1997;8:385-390.
32. Salamone SJ, Courtney JB, Stocker D. 5-Fluoro-uracil derivatives, immunogens, and antibodies and their use in determining therapeutic drug levels in biological samples. US patent 7205,116 B2. April 17, 2007.
33. NCCLS. Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline. 2nd ed. Wayne, Pennsylvania: NCCLS; 2004. NCCLS document EP5-A2 [ISBN 1-56238-542-9].
34. NCCLS. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Wayne, Pennsylvania: NCCLS; 2003. NCCLS document EP6-A [ISBN 1-56238-498-8].
35. Bocci G, Barbara C, Vannozzi F, et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther. 2006;80: 384-395.
36. Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma. Cancer Res. 1987;47: 2203-2206.
37. Jiang H, Jiang J, Hu P, et al. Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;769:169-176.
38. Bi D, Anderson LW, Shapiro J, et al. Measurement of plasma uracil using gas chromatography-mass spectrometry in normal individuals and in patients receiving inhibitors of dihydropyrimidine dehydrogenase. J Chromatogr B Biomed Sci Appl. 2000;738:249-258.
39. Murphy RF, Balis FM, Poplack DG. Stability of 5-fluorouracil in whole blood and plasma. Clin Chem. 1987;33:2299-2300. Erratum in: Clin Chem. 1988;34:1505.